---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-338318"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2025-12-31T23:59:59+00:00"
generated_at: "2026-05-16T11:54:46.348623+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Climb Bio sues Alumis to avoid $3M milestone payment, disputes 'Product' definition under APA

## Summary
- Filed complaint in Delaware Superior Court seeking declaratory judgment that budoprutug is not a 'Product' under the APA.
- Alumis invoiced $3M milestone payment due Jan 1, 2026 for Phase 2 initiation; Climb denies any obligation.
- Climb dosed first patient in Phase 2 trial on Nov 17, 2025; claims no Royalty-Bearing Patents exist to trigger milestone.
- Dispute centers on interpretation of APA; Climb argues no patents transferred or filed within nine months of closing.
- Climb states it attempted to resolve out of court but Alumis refused.

## SEC filing metadata
- accession: 0001193125-25-338318
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2025-12-31T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312525338318/0001193125-25-338318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312525338318/d19559d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-338318
- JSON: https://secwatch.observer/filing/0001193125-25-338318.json
- Plain text: https://secwatch.observer/filing/0001193125-25-338318.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.